Med. praxi. 2013;10(1):22-25

Treatment of diabetes insipidus in adults

prof.MUDr.Jan Čáp, CSc.
IV. interní hematologická klinika, Lékařská fakulta UK a Fakultní nemocnice v Hradci Králové

The cause of diabetes insipidus is either impaired vasopressin secretion (central diabetes insipidus) or lack of its function (nephrogenic

diabetes insipidus). In patients with polyuria it is crucial to rule-out osmotic diuresis and kidney disease. The dehydration test is necessary

for differential diagnosis between diabetes insipidus and primary polydipsia.

Desmopressin has been the drug of choice for central diabetes insipidus for many years. Only sublingual form is available today, when

less than 1 % of administered dose is absorbed. Sufficient compensation is usually achieved by the dose of 120 μg twice a day, sometimes

higher and/or more frequent doses are needed.

Should hyponatraemia appear during treatment the desmopressin dose is decreased; complete withdrawal is dangerous as natraemia

rises too quickly and the patient is in danger of pontine myelinolysis. Patients with impaired thirst sensation represent the major problem.

In nephrogenic diabetes insipidus the diuresis can be decreased by salt restriction with thiazide diuretics and nonsteroide anti-inflammatory

drugs. Some specific types of nephrogenic diabetes insipidus caused by V2 receptor mutations respond to treatment with

soluble non-peptide agonists.

Keywords: diabetes insipidus, diagnosis, treatment/management, polyuria

Published: January 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čáp J. Treatment of diabetes insipidus in adults. Med. praxi. 2013;10(1):22-25.
Download citation

References

  1. Antoni FA, Holmes MC, Makara GB, et al. Evidence that the effects of arginine-8-vasopressin (AVP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor. Peptides 1984; 5: 519-522. Go to original source... Go to PubMed...
  2. Schrier RW. Aquaporin-related disorders of water homeostasis. Drug News Perspect 2007; 20: 447-453. Go to original source... Go to PubMed...
  3. Aleksandrov N, Audibert F, Bedard MJ, et al. Gestational diabetes insipidus: a review of an underdiagnosed condition. J Obstet Gynaecol Can 2010; 32: 225-231. Go to original source... Go to PubMed...
  4. Ananthakrishnan S. Diabetes insipidus in pregnancy: etiology, evaluation, and management. Endocr Pract 2009; 15: 377-382. Go to original source... Go to PubMed...
  5. Sands JM. Urine concentrating and diluting ability during aging. J Gerontol A Biol Sci Med Sci 2012; 67: 1352-1357. Go to original source... Go to PubMed...
  6. Čáp J. Hormonalní poruchy po úrazu mozku. Vnitr Lek 2006; 52: 941-946. Go to PubMed...
  7. De Bellis A, Sinisi AA, Pane E, et al. Involvement of Hypothalamus Autoimmunity in Patients with Autoimmune Hypopituitarism: Role of Antibodies to Hypothalamic Cells. J Clin Endocrinol Metab 2012; 97: 3684-3690. Go to original source... Go to PubMed...
  8. Makaryus AN, Mcfarlane SI. Diabetes insipidus: diagnosis and treatment of a complex disease. Cleve Clin J Med 2006; 73: 65-71. Go to original source... Go to PubMed...
  9. Vavra I, Machova A, Holecek V, et al. Effect of a synthetic analogue of vasopressin in animals and in patients with diabetes insipidus. Lancet 1968; 1: 948-952. Go to original source... Go to PubMed...
  10. Juul KV, Bichet DG, Norgaard JP. Desmopressin duration of antidiuretic action in patients with central diabetes insipidus. Endocrine 2011; 40: 67-74. Go to original source... Go to PubMed...
  11. Lam KS, Wat MS, Choi KL, et al. Pharmacokinetics, pharmacodynamics, long-term efficacy and safety of oral 1-deamino-8-D-arginine vasopressin in adult patients with central diabetes insipidus. Br J Clin Pharmacol 1996; 42: 379-385. Go to original source... Go to PubMed...
  12. Juul KV, Klein BM, Sandstrom R, et al. Gender difference in antidiuretic response to desmopressin. Am J Physiol Renal Physiol2011; 300: F1116-1122. Go to original source... Go to PubMed...
  13. Mavrakis AN, Tritos NA. Diabetes insipidus with deficient thirst: report of a patient and review of the literature. Am J Kidney Dis 2008; 51: 851-859. Go to original source... Go to PubMed...
  14. Los EL, Deen PM, Robben JH. Potential of nonpeptide (ant) agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus. J Neuroendocrinol 2010; 22: 393-399. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.